美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效和安全性分析

Efficacy and Safety of Mesalazine and Sulfasalazine in Treatment of Ulcerative Colitis

目的探讨美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效和安全性。方法选择我院2013年5月至2015年5月收治的溃疡性结肠炎患者80例,随机分为对照组和观察组,每组40例,对照组单纯接受美沙拉嗪治疗,观察组患者给予柳氮磺吡啶治疗。观察两组患者的治疗效果及不良反应发生情况。结果观察组患者治疗总有效率90.0%显著高于对照组的62.5%,差异有统计学意义(P<0.05);观察组患者不良反应发生率7.5%显著低于对照组的27.5%,差异有统计学意义(P<0.05)。结论针对溃疡性结肠炎患者行柳氮磺吡啶治疗,比美沙拉嗪的治疗效果较好,且不良反应较少,安全性高,值得临床推广。

Objective To investigate the efficacy and safety of mesalazine and sulfasalazine in treatment of ulcerative colitis（UC）.Methods 80 UC patients treated in our hospital from May 2013 to May 2015 were selected and randomly divided into control group and observation group, with 40 cases in each group. The control group was only treated with mesalazine, the observation group was treated with sulfasalazine. The treatment effects and incidence of adverse actions were compared between two groups. Results The total effective rate of observation group was 90.0%, significantly higher than 62.5% of control group（P〈0.05）. The incidence of adverse reactions of observation group was 7.5%, significantly lower than 27.5% of control group（P〈0.05）. Conclusions Sulfasalazine has better treatment effect than mesalazine in treating patients with ulcerative colitis, with less adverse reactions and high safety, which is worthy of clinical promotion.